|
| | HR0552 | | LRB103 37043 MST 67158 r |
|
|
1 | | HOUSE RESOLUTION |
2 | | WHEREAS, Cholangiocarcinoma (bile duct cancer) is a rare |
3 | | form of cancer that originates from the cells lining the bile |
4 | | ducts that play a key role in digestion; there are three types |
5 | | of this cancer, intrahepatic, extrahepatic, and perihilar; and |
6 | | WHEREAS, Approximately 12,000 Americans are diagnosed each |
7 | | year with cholangiocarcinoma, with numbers increasing yearly, |
8 | | and the mortality rate has increased dramatically in the last |
9 | | decade; and |
10 | | WHEREAS, Patients are typically diagnosed at a late stage |
11 | | due to the lack of a validated early method of detection; |
12 | | symptoms of jaundice, abdominal pain, itchy skin, and weight |
13 | | loss are symptoms that do not usually present until advanced |
14 | | disease progression; and |
15 | | WHEREAS, Cholangiocarcinoma is a rare cancer; of the top |
16 | | eight deadliest cancers, seven are rare; rare cancers have a |
17 | | five-year survival rate under 50%, with the cholangiocarcinoma |
18 | | five-year survival rate being approximately 20%; and |
19 | | WHEREAS, There is currently no cure for |
20 | | cholangiocarcinoma/bile duct cancer; and |